Skip to main content
SpringerLink
Log in

Evinacumab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The recombinant human monoclonal antibody evinacumab (evinacumab-dgnb, EVKEEZA™) is an angiopoietin-like protein three (ANGPTL3) inhibitor that has been developed by Regeneron Pharmaceuticals for the treatment of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolemia (both familial and non-familial) and severe hypertriglyceridaemia. Based on the results of the phase III ELIPSE HoFH trial, evinacumab was recently approved in the USA as an adjunct to other LDL-C lowering therapies for the treatment of adult and paediatric patients aged 12 years and older with HoFH, and has received a positive opinion in the EU. This article summarizes the milestones in the development of evinacumab leading to this first approval for HoFH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Regeneron Pharmaceuticals. FDA approves first-in-class EVKEEZATM (evinacumab-dgnb) for patients with ultra-rare inherited form of high cholesterol [media release]. 11 Feb 2021. https://investor.regeneron.com.

  2. Regeneron Pharmaceuticals. Regeneron pipeline. 2021. https://www.regeneron.com/pipeline. Accessed 30 Mar 2021.

  3. Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–7.

    Article  Google Scholar 

  4. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–20.

    Article  CAS  Google Scholar 

  5. Regeneron Pharmaceuticals. EVKEEZA™ (evinacumab-dgnb) injection: US prescribing information. 2021. https://www.regeneron.com/sites/default/files/Evkeeza_PI.pdf. Accessed 15 Feb 2021.

  6. European Medicines Agency. Evkeeza (evinacumab): summary of opinion (initial authorisation). 2021. https://www.ema.europa.eu/. Accessed 27 Apr 2021.

  7. Regeneron Pharmaceuticals. Regeneron initiates major global collaboration with Sanofi-Aventis to develop and commercialize fully-human therapeutic antibodies [media release]. 29 Nov 2007. http://www.regeneron.com.

  8. Sanofi Aventis. Sanofi-Aventis and Regeneron expand strategic antibody collaboration [media release]. 11 Nov 2009. http://www.sanofi-aventis.com.

  9. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308–17.

    Article  CAS  Google Scholar 

  10. Harada-Shiba M, Ali S, Gipe DA, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 2020;314:33–40.

    Article  CAS  Google Scholar 

  11. Raal FJ, Rosenson RS, Reeskamp LF, et al. The longer-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia [abstract no. 14407]. Circulation. 2020;142(Suppl 3):A14407.

    Google Scholar 

  12. Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307–19.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Anthony Markham

Authors
  1. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

Changes resulting from any comments received during the peer review process were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Evinacumab: First Approval. Drugs 81, 1101–1105 (2021). https://doi.org/10.1007/s40265-021-01516-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01516-y

Search

Navigation